Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
The multicentre, double-blind, placebo-controlled, randomized trial was done at 386 study sites in 21 countries. The relative risk reduction for the primary composite outcome was consistent in participants with type 2 diabetes and those without diabetes.
